Titre:
  • Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
Auteur:Tate, Sarah K; Depondt, Chantal; Sisodiya, Sanjay M; Cavalleri, Gianpiero L; Schorge, Stephanie; Soranzo, Nicole; Thom, Maria; Sen, Arjune; Shorvon, S.; Sander, Josemir W; Wood, Nicholas W; Goldstein, David B
Informations sur la publication:Proceedings of the National Academy of Sciences of the United States of America, 102, 15, page (5507-5512)
Statut de publication:Publié, 2005-04
Sujet CREF:Neurologie
MeSH keywords:Adolescent
Adult
Aged
Alleles
Amino Acid Sequence
Anticonvulsants -- administration & dosage -- therapeutic use
Aryl Hydrocarbon Hydroxylases -- genetics
Base Sequence
Brain -- metabolism
Carbamazepine -- administration & dosage -- therapeutic use
Child
Child, Preschool
Cohort Studies
Epilepsy -- drug therapy
Exons -- genetics
Female
Genetic Markers -- genetics
Genotype
Humans
Infant
Introns -- genetics
Male
Middle Aged
Molecular Sequence Data
Nerve Tissue Proteins -- genetics
Phenytoin -- administration & dosage -- therapeutic use
Polymorphism, Genetic -- genetics
Sodium Channels -- genetics
Note générale:Journal Article
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0027-8424
info:doi/10.1073/pnas.0407346102
info:pii/0407346102
info:pmid/15805193
PMC556232